Hikma Pharmaceuticals Plc (LON:HIK) has been assigned a consensus recommendation of “Hold” from the eight analysts that are currently covering the stock, MarketBeat Ratings reports. One investment ...
Shares in Hikma Pharmaceuticals (LON:HIK) are currently trading close to a 52 week high, with the share price up by around 6.14% to 2365p over the past week. On a one-month basis, the Hikma ...
StockMarketWire.com - Citigroup today reaffirms its buy investment rating on Hikma Pharmaceuticals PLC [LON:HIK] and raised its price target to 2500p (from 2150p).
Shares of Hikma Pharmaceuticals Plc (LON:HIK) have been given an average recommendation of “Hold” by the eight research firms that are covering the firm, Marketbeat Ratings reports. One equities ...
Interpretation results are anticipated in the coming weeks. Arecor Ltd has inked an agreement with FTSE 100 firm Hikma Pharmaceuticals PLC (LON:HIK) to develop a new, ready-to-use injectable medicine.
Does the November share price for Hikma Pharmaceuticals PLC (LON:HIK) reflect what it's really worth? Today, we will estimate the stock's intrinsic value by projecting its future cash flows and then ...
Hikma Pharmaceuticals Plc (LON:HIK) said it is “successfully” launching new products as it reiterated full-year guidance for 2019. The FTSE 100-listed pharma group said, in a trading statement, that ...
StockMarketWire.com - Barclays Capital today reaffirms its equal weight investment rating on Hikma Pharmaceuticals PLC [LON:HIK] and raised its price target to 1900p (from 1800p).
Hikma Pharmaceuticals announced the appointment of Henriette Nielsen to the newly-created role of chief transformation officer on Monday.
Thomas Cook: Numis downgrades to add with a target price of 159p.
Hikma Pharmaceuticals told shareholders its year had begun with an "encouraging start" on Friday, as they gathered for the annual general meeting, with the global Injectables business particularly said to be performing "well".
Hikma Pharmaceuticals' US subsidiary West-Ward Pharmaceuticals has launched Methotrexate for injection in two doses for the treatment of various cancers.
(WebFG News) - Hikma Pharmaceuticals has launched a generic injectable product to counter a shortage in the US market for products to counter heart problems associated with commonly prescribed chemotherapy drug.
Hikma Pharmaceuticals announced on Thursday that its wholly-owned US subsidiary West-Ward Pharmaceuticals has launched the palonosetron hydrochloride injection at 0.25mg/2mL.
Generic drug maker Hikma Pharmaceuticals said its US subsidiary West-Ward had launched Ritonavir Tablets, the first AB-rated generic to Norvir tablets.
Antofagasta plc: Canaccord upgrades to buy with a target price of 1,090p.
A $920m impairment charge on Hikma Pharmaceuticals' West-Ward Columbus business led to the company reporting a hefty $738m full year pre-tax loss on Wednesday.
Generic drug-maker Hikma Pharmaceuticals will carry out a clinical trial of its generic version of GlaxoSmithKline's Advair Diskus asthma drug after consultation with the US drug regulator.
ITV: Barclays downgrades to equal weight with a target price of 180p.
Hikma Pharmaceuticals announced on Tuesday that its board has appointed Sigurdur 'Siggi' Olafsson as its chief executive officer.